Targeted Approaches Under Assessment in AML

The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leukemia and high-risk myelodysplastic syndrome.

Eric S. Winer, MD, discusses the mechanism of action of emavusertib and preliminary findings from the TakeAim Leukemia trial in acute myeloid leukemia.

Dr Mims discusses the utility of emavusertib in acute myeloid leukemia and myelodysplastic syndrome and the rationale for the TakeAim Leukemia trial.

Alice Mims, MD, discusses the toxicity profile and initial efficacy of emavusertib in heavily pretreated, FLT3-mutated relapsed/refractory AML.

Grzegorz S. Nowakowski, MD, discusses data from the phase 1/2 TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with hematologic malignancies.

Tapan M. Kadia, MD, discusses targeting the IRAK4 pathway in patients with acute myeloid leukemia and highlights the importance of utilizing targeted therapies in the treatment of patients with hematologic malignancies.

Eytan M. Stein, MD, discusses the ongoing development and investigation of therapies targeting splicing mutations in hematologic malignancies.